Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study
نویسندگان
چکیده
منابع مشابه
Anastrozole Versus Exemestane in Patients with Postmenopausal Breast Cancer and Visceral Metastases
Background: For patients with hormone receptor positive metastatic breast cancer (MBC), both steroidal and non-steroidal aromatase inhibitors (AIs) have demonstrated efficacy as initial and subsequent lines of treatment in trials comparing them with other hormonal agents like tamoxifen and megestrol acetate. Patients with MBC and predominant visceral involvement have a shortened survival compar...
متن کاملAbiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer†
BACKGROUND Androgen receptor (AR) signaling and incomplete inhibition of estrogen signaling may contribute to metastatic breast cancer (MBC) resistance to a nonsteroidal aromatase inhibitor (NSAI; letrozole or anastrozole). We assessed whether combined inhibition of androgen biosynthesis with abiraterone acetate plus prednisone and estradiol synthesis with exemestane (E) may be of clinical bene...
متن کاملExemestane for breast-cancer prevention in postmenopausal women.
BACKGROUND Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer. METHODS In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relative reduction in invasive b...
متن کاملExemestane in early breast cancer: a review
The adjuvant treatment of women with endocrine-sensitive early breast cancer has been dominated for the last 40 years by tamoxifen. However, the side-effects associated with this therapy have prompted a search for safer and biochemically more selective endocrine agents and led to the development of the third-generation aromatase inhibitors (AIs) anastrozole, letrozole and exemestane. Promising ...
متن کاملBiomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
PURPOSE Abiraterone may suppress androgens that stimulate breast cancer growth. We conducted a biomarker analysis of circulating tumor cells (CTCs), formalin-fixed paraffin-embedded tissues (FFPETs), and serum samples from postmenopausal estrogen receptor (ER)+ breast cancer patients to identify subgroups with differential abiraterone sensitivity. METHODS Patients (randomized 1:1:1) were trea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Breast Cancer Research and Treatment
سال: 2008
ISSN: 0167-6806,1573-7217
DOI: 10.1007/s10549-008-0229-5